UNSPSC 51263131: Pafenolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AEP5YJ9MZ. European Medicines Agency schedules Pafenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09585MIG. Pafenolol generally arises in the molecular formula C18H31N3O3. The term PAFENOLOL is an International Non-Proprietary Name or INN. PAFENOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule pafenolol under HS 29242190 and SITC 51473. As of Q4 2014, PAFENOLOL remains the US FDA Preferred Term for this commodity. Pafenolol bears US NLM identifiers UMLS ID C0069942 and NCI Concept Code C66291. SMILES: O(CC(O)CNC(C)C)C1CCC(CCNC(=O)NC(C)C)CC1.

UNSPSC 51263131 Pafenolol is a Commodity code nominally identifying a specific pharmaceutical active ingredient, but the recent state and local opportunities posted under it diverge sharply from that scope. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term plus one-year renewal option. Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities and market intelligence on establishing direct-to-manufacturer pharmacy prescription programs, specifically exploring vendor experience with direct contracting, negotiated net pricing models without rebates, and outcomes-based agreements for self-insured employer and state agency health plans. The issuing bodies span state health agencies and county public-health procurement offices, both engaged in pharmaceutical supply and program-design work rather than procurement of pafenolol specifically. The code shows minimal targeted activity under its nominal pharmaceutical scope; the opportunities posted instead reflect broader state and local pharmacy benefit and harm-reduction supply procurement.

Geographic activity centers on Florida and Texas based on the two recent postings. Seminole County's IFB closed in July 2023 (note: the posted date shows June 2026 but the due date references July 2023, suggesting a data-entry artifact or reposted opportunity), requiring vendors to submit bids electronically through the county e-Procurement Portal with all shipping and delivery costs included, compliance with drug-free workplace and E-Verify requirements, and workers' compensation and general liability insurance. The Texas RFI had a response deadline of April 3, 2026 and served as exploratory market research rather than a competitive solicitation, designed to inform the state's strategy before issuing a formal RFP. Neither opportunity specifies set-aside designations or disadvantaged-enterprise restrictions. The code's recent activity signal is weak; firms monitoring state and local pharmaceutical procurement should verify that postings are tagged accurately before committing resources to this code.